Donna
12-14-2006, 03:54 PM
Wow - did you see this! The last line is the best:
: Curr Oncol Rep. (javascript:AL_get(this, 'jour', 'Curr Oncol Rep.');) 2007 Jan;9(1):9-16.<SCRIPT language=JavaScript1.2><!--var PopUpMenu2_LocalConfig_jsmenu3Config = [ ["ShowCloseIcon","yes"], ["Help","window.open('/entrez/query/static/popup.html','Links_Help','resizable=no,scrollbars= yes,toolbar=no,location=no,directories=no,status=n o,menubar=no,copyhistory=no,alwaysRaised=no,depend =no,width=400,height=500');"], ["TitleText"," Links "]]var jsmenu3Config = [ ["UseLocalConfig","jsmenu3Config","",""]]//--></SCRIPT><SCRIPT language=JavaScript1.2><!--var Menu17164042 = [ ["UseLocalConfig","jsmenu3Config","",""], ["Books","window.top.location='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=pubmed_AbstractPlus&cmd=Retrieve&db=pubmed&list_uids=17164042&dopt=Books'","",""]]//--></SCRIPT> Links (javascript:PopUpMenu2_Set(Menu17164042);)
<DD class=abstract id=abstract17164042>The Use of HER2 Modulation in the Adjuvant Setting.
Johnson PH (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Johnson+PH%22%5BAuthor%5D),
Esteva FJ (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Esteva+FJ%22%5BAuthor%5D).
and Molecular & Cellular Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77230-1439, USA. festeva@mdanderson.org.
Amplification of the her-2/neu gene is associated with poor prognosis in patients with early-stage and metastatic breast cancer. Trastuzumab is a humanized monoclonal antibody directed against the HER2 protein, which is overexpressed in approximately 25% of patients with primary invasive breast cancer. Randomized phase III clinical trials showed that administration of trastuzumab in combination with chemotherapy or following chemotherapy significantly improves disease-free and overall survival rates in patients with early-stage HER2-positive breast cancer. The integration of trastuzumab in the adjuvant setting is changing the natural history of HER2-driven breast cancer from one of the worst subtypes to one that is highly curable with available therapy.
PMID: 17164042 [PubMed - in process]
</DD>
: Curr Oncol Rep. (javascript:AL_get(this, 'jour', 'Curr Oncol Rep.');) 2007 Jan;9(1):9-16.<SCRIPT language=JavaScript1.2><!--var PopUpMenu2_LocalConfig_jsmenu3Config = [ ["ShowCloseIcon","yes"], ["Help","window.open('/entrez/query/static/popup.html','Links_Help','resizable=no,scrollbars= yes,toolbar=no,location=no,directories=no,status=n o,menubar=no,copyhistory=no,alwaysRaised=no,depend =no,width=400,height=500');"], ["TitleText"," Links "]]var jsmenu3Config = [ ["UseLocalConfig","jsmenu3Config","",""]]//--></SCRIPT><SCRIPT language=JavaScript1.2><!--var Menu17164042 = [ ["UseLocalConfig","jsmenu3Config","",""], ["Books","window.top.location='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=pubmed_AbstractPlus&cmd=Retrieve&db=pubmed&list_uids=17164042&dopt=Books'","",""]]//--></SCRIPT> Links (javascript:PopUpMenu2_Set(Menu17164042);)
<DD class=abstract id=abstract17164042>The Use of HER2 Modulation in the Adjuvant Setting.
Johnson PH (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Johnson+PH%22%5BAuthor%5D),
Esteva FJ (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Esteva+FJ%22%5BAuthor%5D).
and Molecular & Cellular Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77230-1439, USA. festeva@mdanderson.org.
Amplification of the her-2/neu gene is associated with poor prognosis in patients with early-stage and metastatic breast cancer. Trastuzumab is a humanized monoclonal antibody directed against the HER2 protein, which is overexpressed in approximately 25% of patients with primary invasive breast cancer. Randomized phase III clinical trials showed that administration of trastuzumab in combination with chemotherapy or following chemotherapy significantly improves disease-free and overall survival rates in patients with early-stage HER2-positive breast cancer. The integration of trastuzumab in the adjuvant setting is changing the natural history of HER2-driven breast cancer from one of the worst subtypes to one that is highly curable with available therapy.
PMID: 17164042 [PubMed - in process]
</DD>